Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo

Christina A. Pacak, Cathryn S. Mah, Bijoy D. Thattaliyath, Thomas J. Conlon, Melissa A. Lewis, Denise E. Cloutier, Irene Zolotukhin, Alice F Tarantal, Barry J. Byrne

Research output: Contribution to journalArticle

276 Scopus citations

Abstract

Heart disease is often the end result of inherited genetic defects, which may potentially be treatable using a gene-transfer approach. Recombinant adeno-associated virus (rAAV)-mediated gene delivery has emerged as a realistic method for the treatment of such disorders. Here, we demonstrate and compare the natural affinity of specific AAV serotype capsids for transduction of cardiac tissue. We compared the previously accepted optimal rAAV serotype for transduction of skeletal muscle, rAAV2/1, with rAAV2/8 and the newer rAAV2/9 vectors carrying the CMV-lacZ construct in their respective abilities to transcend vasculature and transduce myocardium following intravenous delivery of 1×10 vector genomes in neonatal mice. We found that both rAAV2/8 and rAAV2/9 are able to transduce myocardium at ≈20- and 200-fold (respectively) higher levels than rAAV2/1. Biodistribution analysis revealed that rAAV2/9 and rAAV2/8 demonstrate similar behavior in extracardiac tissue. Vector genome quantification showed an increase in genome copy numbers in cardiac tissue for several weeks following administration, which corresponds to expression data. In addition, we intravenously administered 1×10 vector genomes of rAAV2/9-CMV-lacZ into adult mice and achieved an expression biodistribution profile similar to that found following delivery to newborns. Although higher doses of virus will be necessary to approach those levels observed following neonatal injections, adult myocardium is also readily transduced by rAAV2/9. Finally, we have demonstrated physiological disease correction by AAV9 gene transfer in a mouse model of Pompe disease via ECG tracings and that intravenous delivery of the same vector preferentially transduces cardiac tissue in nonhuman primates.

Original languageEnglish (US)
JournalCirculation Research
Volume99
Issue number4
DOIs
StatePublished - Aug 2006

Keywords

  • AAV9
  • Adeno-associated virus
  • Cardiomyopathy
  • Gene therapy
  • Gene transfer

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo'. Together they form a unique fingerprint.

  • Cite this

    Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circulation Research, 99(4). https://doi.org/10.1161/01.RES.0000237661.18885.f6